Ordaōs is a New York-based biotechnology company designing mini-proteins to help drug hunters deliver life-saving treatments. Led by CEO David Longo, the company positions itself as human-enabled and machine-driven, leveraging proprietary multitask meta-learning and reinforcement learning. Ordaōs uses the Ordaōs Design Engine to generate, appraise, and rank billions of protein sequences and hundreds of thousands of protein structures and properties to create customized miniPRO™ proteins. These proteins are rapidly evaluated in vitro to provide intelligent feedback on multiple design objectives, including structure, binding specificity and affinity, solubility, stability, immunogenicity, and developability. The iterative, continuous-learning process translates human-targeted product criteria into optimized mini-proteins intended to meet a client's molecular target product profile and enable targeted therapies that reduce patient suffering and extend life. The company raised $5M in Seed funding to support these efforts.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2022